Boehringer Ingelheim partners with Envisagenics on $1 billion AI-driven oncology collaboration

Boehringer Ingelheim and AI drug discovery firm Envisagenics have signed a potential $1 billion multi‑year agreement to validate tumor‑specific targets. The deal will see Boehringer use Envisagenics' SpliceCore platform, which applies artificial intelligence to RNA splicing data, to identify and prioritize cancer‑specific isoforms.

Envisagenics said the upfront and milestone payments will support the advancement of its lead central nervous system candidate into clinical testing. SpliceCore screens more than 14 million splicing events and predicts disease specificity, patient prevalence and therapeutic suitability.

The collaboration gives Boehringer the opportunity to evaluate identified targets for development into antibody‑drug conjugates, T‑cell engagers and multispecific antibodies, aiming to create therapies that distinguish cancer cells from healthy tissue.